OS Therapies (NYSEAMERICAN:OSTX) Price Target Lowered to $13.00 at Lake Street Capital

OS Therapies (NYSEAMERICAN:OSTX) had its price target cut by Lake Street Capital from $14.00 to $13.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

A number of other equities research analysts have also recently issued reports on the stock. Zacks Research cut shares of OS Therapies from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. D. Boral Capital reaffirmed a “buy” rating and set a $20.00 price target on shares of OS Therapies in a research report on Thursday, April 30th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $16.50.

OS Therapies Stock Performance

OS Therapies stock traded down $0.02 during midday trading on Tuesday, reaching $1.71. The stock had a trading volume of 118,334 shares, compared to its average volume of 646,834. The stock has a market capitalization of $67.60 million, a P/E ratio of -1.72 and a beta of -1.34. The firm’s fifty day simple moving average is $1.52 and its 200-day simple moving average is $1.55. OS Therapies has a 1-year low of $1.15 and a 1-year high of $2.57.

OS Therapies (NYSEAMERICAN:OSTX) last issued its quarterly earnings results on Monday, May 18th. The company reported ($0.27) earnings per share for the quarter. On average, sell-side analysts anticipate that OS Therapies will post 0.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On OS Therapies

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC bought a new stake in shares of OS Therapies during the 3rd quarter valued at $183,000. Two Sigma Investments LP bought a new position in shares of OS Therapies in the third quarter worth $169,000. Geode Capital Management LLC raised its stake in OS Therapies by 31.1% in the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock valued at $344,000 after purchasing an additional 58,350 shares in the last quarter. Virtu Financial LLC raised its stake in OS Therapies by 252.0% in the third quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock valued at $149,000 after purchasing an additional 54,269 shares in the last quarter. Finally, XTX Topco Ltd bought a new stake in OS Therapies during the second quarter worth about $63,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.